Transmissible Spongiform Encephalopathies Advisory Committee; Notice of Meeting, 69134-69135 [E6-20251]
Download as PDF
<![CDATA[
69134
Federal Register / Vol. 71, No. 229 / Wednesday, November 29, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Court Improvement Program—
New Grants.
OMB No.: 0970–0307.
Description: The President signed the
Deficit Reduction Act of 2005 (DRA),
Public Law 109–171, into law on
February 8, 2006. The law authorizes
and appropriates funds for two new
grants under the Court Improvement
Program in title IV–B, section 438, of the
Social Security Act. The highest State
court in a State with an approved title
IV–E plan is eligible to apply for either
or both of the new grants. The new
grants are for the purposes of (1)
Ensuring that the needs of children are
met in a timely and complete manner
through improved case tracking and
analysis of child welfare cases, and (2)
training judges, attorneys, and other
legal personnel in child welfare cases
and conducting cross-training with
child welfare agency staff and
contractors.
The DRA requires separate
applications for these two new grants.
The annual burden estimates below
describe the estimated annual burden
for the two new grants. The
Administration for Children and
Families (ACF) proposes to collect
Number of
respondents
Instrument
Application .......................................................................................................
Annual Program Report ...................................................................................
Estimated Total Annual Burden
Hours: 7,904.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Attn: Desk Officer for
ACF, E-mail address:
Karen_Y._Matsuoka@omb.eop.gov.
jlentini on PROD1PC65 with NOTICES
Dated: November 21, 2006.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 06–9440 Filed 11–28–06; 8:45 am]
BILLING CODE 4184–01–M
Food and Drug Administration
[Docket No. 2005N–0097]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Experimental Study of Qualified Health
Claims: Consumer Inferences About
Monounsaturated Fatty Acids From
Olive Oil, EPA and DHA Omega-3 Fatty
Acids, and Green Tea
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Experimental Study of Qualified
Health Claims: Consumer Inferences
About Monounsaturated Fatty Acids
From Olive Oil, [eicosapentaenoic acid]
EPA and [docosahexaenoic acid] DHA
Omega-3 Fatty Acids, and Green Tea’’
has been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
In the
Federal Register of May 22, 2006 (71 FR
29340), the agency announced that the
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
15:37 Nov 28, 2006
Jkt 211001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Number of responses per
respondent
52
52
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
information from the States about their
work under these grants (applications,
program reports) by way of a Program
Instruction that was issued on June 15,
2006. This Program Instruction
described the programmatic and fiscal
provisions and reporting requirements
for each of the grants, specified the
application submittal and approval
procedures for the grants for fiscal years
2006 through 2010, and identified
technical resources for use by State
courts during the course of the grants.
ACF will use the information received
to ensure compliance with the DRA and
provide training and technical
assistance to the grantees.
Respondents: State courts.
Annual Burden Estimates:
Average
burden huors
per response
2
2
Total burden
hours
40
36
4,160
3,744
proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0592. The
approval expires on November 30, 2009.
A copy of the supporting statement for
this information collection is available
on the Internet at https://www.fda.gov/
ohrms/dockets.
Dated: November 22, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–20200 Filed 11–28–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Transmissible Spongiform
Encephalopathies Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
E:\FR\FM\29NON1.SGM
29NON1
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 71, No. 229 / Wednesday, November 29, 2006 / Notices
Name of Committee: Transmissible
Spongiform Encephalopathies Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 15, 2006, from 8 a.m.
to 3:30 p.m.
Location: Crown Plaza Silver Spring,
8777 Georgia Ave., Silver Spring, MD.
The hotel telephone number is 301–
589–0800.
Contact Person: William Freas, or
Rosanna L. Harvey, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852–
1448, 301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512392. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: On December 15, 2006, the
committee will discuss FDA’s risk
assessment for potential exposure to
variant Creutzfeldt-Jakob disease in
human plasma-derived antihemophilic
factor (FVIII) products manufactured
from U. S. plasma donors and related
communication materials. In the
afternoon, the committee will discuss
levels of transmissible spongiform
encephalopathy clearance in the
manufacture of plasma-derived Factor
VIII products. FDA intends to make
background material available to the
public no later than one business day
before the meeting. If FDA is unable to
post the background material on its Web
site prior to the meeting, the background
material will be made publicly available
at the location of the advisory
committee meeting, and the background
material will be posted on FDA’s Web
site after the meeting. Background
material is available at https://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm, click on the year 2006 and
scroll down to the appropriate advisory
committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before December 11, 2006.
Oral presentations from the public will
be scheduled between approximately
10:25 and 10:55 a.m. and 1:35 and 2:05
p.m. on December 15, 2006. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
VerDate Aug<31>2005
15:37 Nov 28, 2006
Jkt 211001
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
December 7, 2006. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by December 8, 2006.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact William
Freas or Rosanna L. Harvey at least 7
days in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: November 22, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–20251 Filed 11–28–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Statement of Organization, Functions
and Delegations of Authority
This notice amends Part R of the
Statement of Organization, Functions
and Delegations of Authority of the
Department of Health and Human
Services (HHS), Health Resources and
Services Administration (HRSA) (60 FR
56605, as amended November 6, 1995;
67 FR 46519, July 15,2002; and 68 FR
787–793, January 7, 2003; 68 FR 64357–
64357, November 13, 2003; 68 FR
64357–64357–64358, and as last
amended at 70 FR 42347–42348, July
22, 2005.)
This notice reflects organizational
changes in the Health Resources and
Services Administration, Bureau of
Primary Health Care (RC). Specifically,
this notice updates the functional
statements of the Bureau of Primary
Health Care.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
69135
Chapter RC—Office of the Associate
Administrator
Section RC–10, Organization
Delete in its entirety and replace with
the following: The Bureau of Primary
Health Care (BPHC) is headed by an
Associate Administrator, who reports
directly to the Administrator, Health
Resources and Services Administration.
The Bureau of Primary Health Care
includes the following components:
(1) Office of the Associate
Administrator (RC);
(2) Office of Minority and Special
Populations (RCG);
(3) Office of Policy and Program
Development (RCH);
(4) Office of Quality and Data (RCK);
(5) Office of Administrative
Management (RCM);
(6) Eastern Division (RCN);
(7) Central Mid-Atlantic Division
(RCP);
(8) Western Division (RCQ);
(9) Division of National Hansen’s
Disease Programs (RC7); and
(10) Division Immigration Health
Service (RC9).
Section RC–20, Functions
(1) Delete the functional statement for
the Office of the Associate
Administrator (RC) and replace in its
entirety; (2) Establish the Office of
Administrative Management (RCM); (3)
Delete the Division of Health Center
Management (RCJ) in its entirety and
replace with the following new
Divisions: Eastern Division (RCN),
Central Mid-Atlantic Division (RCP),
and Western Division (RCQ); (4) Delete
the Division of State and Community
Assistance (RCL) in its entirety; (5) Retitle the Division of Policy and
Development (RCH) as the Office of
Policy and Program Development (RCH)
and replace its functional statement in
its entirety; (6) Re-title the Division of
Clinical Quality (RCK) as the Office of
Quality and Data (RCK) and replace its
functional statement in its entirety; and
(7) Delete the functional statement for
the Office of Minority and Special
Populations (RCG) and replace in its
entirety.
Office of the Associate Administrator
(RC)
Provides overall leadership, direction,
coordination, and planning in support
of Bureau programs: (1) Establishes
program goals, objectives and priorities,
and provides oversight as to their
execution; (2) plans, directs, coordinates
and evaluates Bureau-wide management
activities; and (3) maintains effective
relationships within HRSA and with
other Department of Health and Human
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 71, Number 229 (Wednesday, November 29, 2006)]
[Notices]
[Pages 69134-69135]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Transmissible Spongiform Encephalopathies Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
[[Page 69135]]
Name of Committee: Transmissible Spongiform Encephalopathies
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 15, 2006, from
8 a.m. to 3:30 p.m.
Location: Crown Plaza Silver Spring, 8777 Georgia Ave., Silver
Spring, MD. The hotel telephone number is 301-589-0800.
Contact Person: William Freas, or Rosanna L. Harvey, Center for
Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-
0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-
443-0572 in the Washington, DC area), code 3014512392. Please call the
Information Line for up-to-date information on this meeting.
Agenda: On December 15, 2006, the committee will discuss FDA's risk
assessment for potential exposure to variant Creutzfeldt-Jakob disease
in human plasma-derived antihemophilic factor (FVIII) products
manufactured from U. S. plasma donors and related communication
materials. In the afternoon, the committee will discuss levels of
transmissible spongiform encephalopathy clearance in the manufacture of
plasma-derived Factor VIII products. FDA intends to make background
material available to the public no later than one business day before
the meeting. If FDA is unable to post the background material on its
Web site prior to the meeting, the background material will be made
publicly available at the location of the advisory committee meeting,
and the background material will be posted on FDA's Web site after the
meeting. Background material is available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the year 2006 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
December 11, 2006. Oral presentations from the public will be scheduled
between approximately 10:25 and 10:55 a.m. and 1:35 and 2:05 p.m. on
December 15, 2006. Those desiring to make formal oral presentations
should notify the contact person and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
December 7, 2006. Time allotted for each presentation may be limited.
If the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by December 8,
2006.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact William Freas or
Rosanna L. Harvey at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: November 22, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-20251 Filed 11-28-06; 8:45 am]
BILLING CODE 4160-01-S
